ExenatideAcetateCASExenatide,anincretinmimicpeptidecomprisedof39aminoacidresidue,isanewantidiabeticdrugapprovedbyFDAin2005forthetreatmentofdiabetesmellitustype2.Themainphysiologicalfuncti***arefollowings:Promoteinsulinexcretioninglucose-dependencemanner,restorationofglucosesensitivitytotheislets,inhibitionofapoptosisofexistingcellsandincreasethenumberofβCells,inhibitionofgastricemptyingleadstodecreasedfoodintakeandreducedbodyweight.Theexenatidetherapyhasthefollowingadvantagestocomparewithinsulintherapy:Nohypoglycemiaeffect,reducingbodyweight,improvinginsulinresistance,promotingisletscellfunctionofpatients.Exenatideisdevelopedandmarketed(brandnameByetta)byAmylinPharmaceuticalsandEliLillyandCompany.Duetosomehistoricalreas***,thereisnocompoundpatentforthedruginmanycountries.TheAPIofthedrugandgenericsh***ebeendevelopedandcurrentlyunderclinicaltrialinChina.BeyelPharmaceuticaliscapableofmanufacturingExenatideAcetatebysolidphasesynthesisunderGMPcompliance.Essentialinformation:Molecularformula:C184H282N50O60SMolecularweight:4186.61Qualitystandard:Pleasecontactusifyouwanttoknowthedetail.)